Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 212

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy

Open access
Upadhyay, Ranjan, Boiarsky, Jonathan A., Pantsulaia, Gvantsa, Svensson-Arvelund, Judit, Lin, Matthew J., Wroblewska, Aleksandra, Bhalla, Sherry, Scholler, Nathalie, Bot, Adrian, Rossi, John M., Sadek, Norah, Parekh, Samir, Lagana, Alessandro, Baccarini, Alessia, Merad, Miriam, Brown, Brian D., Brody, Joshua D. · 2021 · Cancer Discovery

Abstract

T cell–based therapies have induced cancer remissions, though most tumors ultimately progress, reflecting inherent or acquired resistance including antigen escape. Better understanding of how T cells eliminate tumors will help decipher resistance mechanisms. We used a CRISPR/Cas9 screen and identified a necessary role for Fas–FasL in antigen-specific T-cell killing. We also found that Fas–FasL mediated off-target “bystander” killing of antigen-negative tumor cells. This localized bystander cytotoxicity enhanced clearance of antigen-heterogeneous tumors in vivo, a finding that has not been shown previously. Fas-mediated on-target and bystander killing was reproduced in chimeric antigen receptor (CAR-T) and bispecific antibody T-cell models and was augmented by inhibiting regulators of Fas signaling. Tumoral FAS expression alone predicted survival of CAR-T–treated patients in a large clinical trial (NCT02348216). These data suggest strategies to prevent immune escape by targeting both the antigen expression of most tumor cells and the geography of antigen-loss variants. Significance: This study demonstrates the first report of in vivo Fas-dependent bystander killing of antigen-negative tumors by T cells, a phenomenon that may be contributing to the high response rates of antigen-directed immunotherapies despite tumoral heterogeneity. Small molecules that target the Fas pathway may potentiate this mechanism to prevent cancer relapse. This article is highlighted in the In This Issue feature, p. 521

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-0756

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 212

Metadata

Authors
Upadhyay, R., Boiarsky, J. A., Pantsulaia, G., Svensson-Arvelund, J., Lin, M. J., Wroblewska, A., Bhalla, S., Scholler, N., Bot, A., Rossi, J. M., Sadek, N., Parekh, S., Lagana, A., Baccarini, A., Merad, M., Brown, B. D., & Brody, J. D.
Venue
Cancer Discovery
Published
2021-03-01
Volume
11
Issue
3
Pages
599-613
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3111766121
Cited by
212
References
22
FWCI
10.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-0756
The paper
Upadhyay, R., Boiarsky, J. A., Pantsulaia, G., Svensson-Arvelund, J., Lin, M. J., Wroblewska, A., Bhalla, S., Scholler, N., Bot, A., Rossi, J. M., Sadek, N., Parekh, S., Lagana, A., Baccarini, A., Merad, M., Brown, B. D., & Brody, J. D. (2021). A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-0756

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.